Fernando P. Secin
Research Subjects
Fernando P. Secin has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Marc Galiano
Clinique de l'Alma, Urology , Paris , France
6 shared publications - Xavier Cathelineau
Paris, France
6 shared publications E. Barret
5 shared publicationsF. Rozet
5 shared publicationsD. Prapotnich
4 shared publicationsA. Mombet
3 shared publications
Latest Publications
- Open Access
- 2 July 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-9
Small renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis – a multi-institutional study from LARCG database
Background: To evaluate demographic, clinical and pathological characteristics of small renal masses (SRM) (≤ 4 cm) in a Latin-American population provided by LARCG (Latin-American Renal Cancer Group) and analyze predictors of survival, recurrence and metastasis. Methods: A multi-institutional retrospective cohort study of 1523 patients submitted to surgical treatment for non-metastatic SRM from 1979 to 2016. Comparisons between radical (RN) or partial nephrectomy (PN) and young or elderly patients were performed. Kaplan-Meier curves and log-rank tests estimated 10-year overall survival. Predictors of local recurrence or metastasis were analyzed by a multivariable logistic regression model. Results: PN and RN were performed in 897 (66%) and 461 (34%) patients. A proportional increase of PN cases from 48.5% (1979–2009) to 75% (after 2009) was evidenced. Stratifying by age, elderly patients (≥ 65 years) had better 10-year OS rates when submitted to PN (83.5%), than RN (54.5%), p = 0.044. This disparity was not evidenced in younger patients. On multivariable model, bilaterality, extracapsular extension and ASA (American Society of Anesthesiologists) classification ≥3 were predictors of local recurrence. We did not identify significant predictors for distant metastasis in our series. Conclusions: PN is performed in Latin-America in a similar proportion to developed areas and it has been increasing in the last years. Even in elderly individuals, if good functional status, sufficiently fit to surgery, and favorable tumor characteristics, they should be encouraged to perform PN. Intending to an earlier diagnosis of recurrence or distant metastasis, SRM cases with unfavorable characteristics should have a more rigorous follow-up routine.
- 2 July 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-9
Open AccessSmall renal masses in Latin-American population: characteristics and prognostic factors for survival, recurrence and metastasis – a multi-institutional study from LARCG database
Background: To evaluate demographic, clinical and pathological characteristics of small renal masses (SRM) (≤ 4 cm) in a Latin-American population provided by LARCG (Latin-American Renal Cancer Group) and analyze predictors of survival, recurrence and metastasis. Methods: A multi-institutional retrospective cohort study of 1523 patients submitted to surgical treatment for non-metastatic SRM from 1979 to 2016. Comparisons between radical (RN) or partial nephrectomy (PN) and young or elderly patients were performed. Kaplan-Meier curves and log-rank tests estimated 10-year overall survival. Predictors of local recurrence or metastasis were analyzed by a multivariable logistic regression model. Results: PN and RN were performed in 897 (66%) and 461 (34%) patients. A proportional increase of PN cases from 48.5% (1979–2009) to 75% (after 2009) was evidenced. Stratifying by age, elderly patients (≥ 65 years) had better 10-year OS rates when submitted to PN (83.5%), than RN (54.5%), p = 0.044. This disparity was not evidenced in younger patients. On multivariable model, bilaterality, extracapsular extension and ASA (American Society of Anesthesiologists) classification ≥3 were predictors of local recurrence. We did not identify significant predictors for distant metastasis in our series. Conclusions: PN is performed in Latin-America in a similar proportion to developed areas and it has been increasing in the last years. Even in elderly individuals, if good functional status, sufficiently fit to surgery, and favorable tumor characteristics, they should be encouraged to perform PN. Intending to an earlier diagnosis of recurrence or distant metastasis, SRM cases with unfavorable characteristics should have a more rigorous follow-up routine.
- Open Access
- 1 July 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (suppl 1) , 79-85
Priorities in testis cancer care during Covid-19 Pandemic
Introduction: There is little information on how to prioritize testis cancer (TC) patients' care during COVID-19 pandemic in order to relieve its pressure on the health care systems. Objective: To describe the recommendations for diagnosis, treatment and follow-up of patients with TC amidst COVID- 19 pandemic. Material and Methods: Pubmed search and review of the main urological association guidelines on TC. Results: The biology of TC requires immediate care of patients during diagnosis, initial surgical therapy and management of recurrent disease. Active surveillance is the first choice of management and should be offered to all compliant clinical stage I TC patients provided they understand the need to self-isolate. Active surveillance may also help decrease the demand for intensive care unit beds, ventilators, personal protective equipment, and other critical hospital and human resources by minimizing surgeries without compromising patient outcomes. Complications of therapy and symptomatic patients represent medical emergencies and should be treated immediately. Telemedicine may be useful during follow-up periods. Conclusions: Most stages of testis cancer require urgent care; however, all recommendations must be adapted to local health care priorities considering that most of these patients are at low risk of severe COVID-19 infection.
- 1 July 2020
- Published by FapUNIFESP (SciELO) in International braz j urol
- Vol. 46 (suppl 1) , 79-85
Open AccessPriorities in testis cancer care during Covid-19 Pandemic
Introduction: There is little information on how to prioritize testis cancer (TC) patients' care during COVID-19 pandemic in order to relieve its pressure on the health care systems. Objective: To describe the recommendations for diagnosis, treatment and follow-up of patients with TC amidst COVID- 19 pandemic. Material and Methods: Pubmed search and review of the main urological association guidelines on TC. Results: The biology of TC requires immediate care of patients during diagnosis, initial surgical therapy and management of recurrent disease. Active surveillance is the first choice of management and should be offered to all compliant clinical stage I TC patients provided they understand the need to self-isolate. Active surveillance may also help decrease the demand for intensive care unit beds, ventilators, personal protective equipment, and other critical hospital and human resources by minimizing surgeries without compromising patient outcomes. Complications of therapy and symptomatic patients represent medical emergencies and should be treated immediately. Telemedicine may be useful during follow-up periods. Conclusions: Most stages of testis cancer require urgent care; however, all recommendations must be adapted to local health care priorities considering that most of these patients are at low risk of severe COVID-19 infection.
- 19 February 2018
- Published by Springer Nature in World Journal of Urology
- Vol. 36 (4) , 595-601
Robotic surgery in public hospitals of Latin-America: a castle of sand?
There is no information about the evolution of robotic programs in public hospitals of Latin-America.
- 19 February 2018
- Published by Springer Nature in World Journal of Urology
- Vol. 36 (4) , 595-601
Robotic surgery in public hospitals of Latin-America: a castle of sand?
There is no information about the evolution of robotic programs in public hospitals of Latin-America.
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e29-e31
Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e29-e31
Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1314-e1315
Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy
- 1 March 2017
- Published by Elsevier in European Urology Supplements
- Vol. 16 (3) , e1314-e1315
Prospective comparative analysis of oncologic and functional outcomes between focal therapy and robotic radical prostatectomy
- 1 October 2016
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 34 (10) , 423-426
Questionable oncologic benefits of degarelix
- 1 October 2016
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 34 (10) , 423-426
Questionable oncologic benefits of degarelix
- 30 April 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (1) , 57-65
American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy
To describe the perioperative and oncology outcomes in a series of laparoscopic or robotic partial nephrectomies (PN) for renal tumors treated in diverse institutions of Hispanic America from the beginning of their minimally invasive (MI) PN experience through December 2014. Seventeen institutions participated in the CAU generated a MI PN database. We estimated proportions, medians, 95 % confidence intervals, Kaplan-Meier curves, multivariate logistic and Cox regression analyses. Clavien-Dindo classification was used. We evaluated 1501 laparoscopic (98 %) or robotic (2 %) PNs. Median age: 58 years. Median surgical time, warm ischemia and intraoperative bleeding were 150, 20 min and 200 cc. 81 % of the lesions were malignant, with clear cell histology being 65 % of the total. Median maximum tumor diameter is 2.7 cm, positive margin is 8.2 %, and median hospitalization is 3 days. One or more postoperative complication was recorded in 19.8 % of the patients: Clavien 1: 5.6 %; Clavien 2: 8.4 %; Clavien 3A: 1.5 %; Clavien 3B: 3.2 %; Clavien 4A: 1 %; Clavien 4B: 0.1 %; Clavien 5: 0 %. Bleeding was the main cause of a reoperation (5.5 %), conversion to radical nephrectomy (3 %) or open partial nephrectomy (6 %). Transfusion rate is 10 %. In multivariate analysis, RENAL nephrometry score was the only variable associated with complications (OR 1.1; 95 % CI 1.02-1.2; p = 0.02). Nineteen patients presented disease progression or died of disease in a median follow-up of 1.37 years. The 5-year progression or kidney cancer mortality-free rate was 94 % (95 % CI 90, 97). Positive margins (HR 4.98; 95 % CI 1.3-19; p = 0.02) and females (HR 5.6; 95 % CI 1.7-19; p = 0.005) were associated with disease progression or kidney cancer mortality after adjusting for maximum tumor diameter. Laparoscopic PN in these centers of Hispanic America seem to have acceptable perioperative complications and short-term oncologic outcomes.
- 30 April 2016
- Published by Springer Nature in World Journal of Urology
- Vol. 35 (1) , 57-65
American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy
To describe the perioperative and oncology outcomes in a series of laparoscopic or robotic partial nephrectomies (PN) for renal tumors treated in diverse institutions of Hispanic America from the beginning of their minimally invasive (MI) PN experience through December 2014. Seventeen institutions participated in the CAU generated a MI PN database. We estimated proportions, medians, 95 % confidence intervals, Kaplan-Meier curves, multivariate logistic and Cox regression analyses. Clavien-Dindo classification was used. We evaluated 1501 laparoscopic (98 %) or robotic (2 %) PNs. Median age: 58 years. Median surgical time, warm ischemia and intraoperative bleeding were 150, 20 min and 200 cc. 81 % of the lesions were malignant, with clear cell histology being 65 % of the total. Median maximum tumor diameter is 2.7 cm, positive margin is 8.2 %, and median hospitalization is 3 days. One or more postoperative complication was recorded in 19.8 % of the patients: Clavien 1: 5.6 %; Clavien 2: 8.4 %; Clavien 3A: 1.5 %; Clavien 3B: 3.2 %; Clavien 4A: 1 %; Clavien 4B: 0.1 %; Clavien 5: 0 %. Bleeding was the main cause of a reoperation (5.5 %), conversion to radical nephrectomy (3 %) or open partial nephrectomy (6 %). Transfusion rate is 10 %. In multivariate analysis, RENAL nephrometry score was the only variable associated with complications (OR 1.1; 95 % CI 1.02-1.2; p = 0.02). Nineteen patients presented disease progression or died of disease in a median follow-up of 1.37 years. The 5-year progression or kidney cancer mortality-free rate was 94 % (95 % CI 90, 97). Positive margins (HR 4.98; 95 % CI 1.3-19; p = 0.02) and females (HR 5.6; 95 % CI 1.7-19; p = 0.005) were associated with disease progression or kidney cancer mortality after adjusting for maximum tumor diameter. Laparoscopic PN in these centers of Hispanic America seem to have acceptable perioperative complications and short-term oncologic outcomes.
- 1 February 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (4_suppl) , 150
PSA patterns during off-time treatment period in patients undergoing intermittent androgen deprivation: Is PSA doubling time reliable in every case?
150 Background: Indicators such as prostate-specific antigen (PSA) nadir after the first on-treatment period (ONTP), off-phase interval duration and PSA doubling time (PSADT) were interpreted as potentially predictive, regarding outcomes of intermittent androgen deprivation (IAD). From actual PSA measurement data recorded on patients undergoing IAD during their off-treatment period (OFTP), we conducted a systematic analysis aimed at screening indicators and finely assessing their relevance as predictive candidates. Methods: Between 1992 and 2012, 727 patients with PC were selected for IAD at our institution. Three hundred ten patients had biochemical recurrence (BCR) after local treatment, 172 showed metastatic disease. ONTP consisted of three-month dose injections of gonadatropin-releasing hormone (GnRH) agonist combined with daily oral androgen receptor antagonist. OFTP was indicated when PSA was less than 4 ng/ml. Criteria for resumption of hormonal therapy were PSA more than 20 ng/ml or clinical symptoms. We tested two basic patterns of PSA behavior-exponential and power law (a<1) and combinations of them, on 597 patients with at least one completed OFTP based on four visits or more (population of the study). Results: We identified 597 patients with a total of 1,573 OFTPs. Median follow-up was 12,2 months (3,0-132,6). Median age at initiation was 76,7 (56,7 to 88,5); 811 OFTPs (51,6%) fitted with a pure exponential (r=0,01), whereas the other part (48,4%) followed more complex patterns (power law or two-steps or linear pattern). Mean cancer specific survival duration was 77,4 months (13,5 to 179,8). 5- and 10-year PC survival rate were respectively of 89,3% and 65,2% (CI 95%). Conclusions: Some OFTPs do not present an exponential pattern behavior: logarithmic calculation of PSADT is not suitable. PSADT determination should be adapted to the nature of the OFTP pattern. Through identification and analysis of the different types of OFTP, it is expected to improve the forecast of clinical outcomes.
- 1 February 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (4_suppl) , 150
PSA patterns during off-time treatment period in patients undergoing intermittent androgen deprivation: Is PSA doubling time reliable in every case?
150 Background: Indicators such as prostate-specific antigen (PSA) nadir after the first on-treatment period (ONTP), off-phase interval duration and PSA doubling time (PSADT) were interpreted as potentially predictive, regarding outcomes of intermittent androgen deprivation (IAD). From actual PSA measurement data recorded on patients undergoing IAD during their off-treatment period (OFTP), we conducted a systematic analysis aimed at screening indicators and finely assessing their relevance as predictive candidates. Methods: Between 1992 and 2012, 727 patients with PC were selected for IAD at our institution. Three hundred ten patients had biochemical recurrence (BCR) after local treatment, 172 showed metastatic disease. ONTP consisted of three-month dose injections of gonadatropin-releasing hormone (GnRH) agonist combined with daily oral androgen receptor antagonist. OFTP was indicated when PSA was less than 4 ng/ml. Criteria for resumption of hormonal therapy were PSA more than 20 ng/ml or clinical symptoms. We tested two basic patterns of PSA behavior-exponential and power law (a<1) and combinations of them, on 597 patients with at least one completed OFTP based on four visits or more (population of the study). Results: We identified 597 patients with a total of 1,573 OFTPs. Median follow-up was 12,2 months (3,0-132,6). Median age at initiation was 76,7 (56,7 to 88,5); 811 OFTPs (51,6%) fitted with a pure exponential (r=0,01), whereas the other part (48,4%) followed more complex patterns (power law or two-steps or linear pattern). Mean cancer specific survival duration was 77,4 months (13,5 to 179,8). 5- and 10-year PC survival rate were respectively of 89,3% and 65,2% (CI 95%). Conclusions: Some OFTPs do not present an exponential pattern behavior: logarithmic calculation of PSADT is not suitable. PSADT determination should be adapted to the nature of the OFTP pattern. Through identification and analysis of the different types of OFTP, it is expected to improve the forecast of clinical outcomes.
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e679-e680
679 PSA patterns during Off-time treatment period in patients undergoing intermittent androgen deprivation. Is PSA doubling time reliable in every case?
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e679-e680
679 PSA patterns during Off-time treatment period in patients undergoing intermittent androgen deprivation. Is PSA doubling time reliable in every case?
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e589-e590
589 Limitation of the current criteria for biochemical recurrence (BCR) after high intensity ultrasound (HIFU) in localized prostate cancer
- 1 March 2013
- Published by Elsevier in European Urology Supplements
- Vol. 12 (1) , e589-e590
589 Limitation of the current criteria for biochemical recurrence (BCR) after high intensity ultrasound (HIFU) in localized prostate cancer